 Maps recently raised $30 million, which clearly shows that there is a huge interest in the psychedelic industry. Joining me now is Simeon Schnapper. He has been very involved in the industry. Plus he has his own plant touching venture fund called JLS. What did you make of this $30 million investment? Because Maps is a nonprofit. So these are people that are investing money into a company for lack of a better word that they're really not gonna get like the money back. Yeah, first and foremost, that was such a cool moment. Like I remember when it was first announced and it's not an insignificant amount of capital, right? 30 million is a lot. And to see how fast it was raised and who donated was phenomenal. And I think people are generally seeing that we're at this, I think it was Tim who said, bending the arc of history, which is one of his bylines, Tim Ferriss. Tim Ferriss. Incremental in helping to really feel to the fire as it revolved around the capstone. But I think generally people want to see this succeed. And there's definitely other industries where nonprofits are the focus until a capital market can exist for it. So anyone donating into that believes it in their heart, sees the mental health epidemic, sees the power and significance of these molecules, a harm reduction, different modalities of healing people. And I would be shocked if any of the people who donated into the nonprofit are also not looking at this as an industry to some extent. It may have investments on companies that are mission driven but also have a component of you're making an investment. We expect you to get X of a return over a Y period of time. Well, there's certainly going to be benefits down the road. So if maps does get this money and is able to do these studies and then they come out at the end and they say we did this study and here's the results that this psychedelic treatment will help PTSD, will help addiction, will help treat drug resistant depression. So that certainly opens up a capitalistic opportunity for a lot of other companies. So yes, if they are invested in other companies then it only behooves them to have the scientific data to support the treatments. Yeah, and in fact, a lot of the scientific data is necessary for the capitalization to even occur. I mean, a lot of people say, building on the shoulder of giants, maps has gone so much. And this is inclusive of Beckley and Hector and a half a dozen others to really put in the forefront that these medicines are medicine. And at a time in history where the magnifying glasses are so attributed to mental health and it's so on everything that's happening around mental health, it just kind of is a no-brainer that everything around capstone is going to create a mushrooming other opportunities. And some might be bad, some might be good, some might be for-profit, some might be really cool models on cap cooperatives or have ethicists on their board. But that renaissance, which I've been waiting for for a few decades, decades is certainly upon us. And it sounds like the exit, if people are looking to exit, that's way out. It's certainly not like cannabis where you had people that were in and out within a couple of years. This looks like a good three to five year commitment for most of these investors in not necessarily the public companies, which you can buy and sell the stock in, but some of these, even if you're investing in a public company or a private company, there's really not gonna be that payoff for it seems easily like three to five years. Well, we have, in our fund, we set a horizon of three years just because we're seeing a lot of different things. Obviously with the rights to extend that, I do think there's a misnomer that an exit is gonna happen when something goes through FDA trials, the whole long tail there, or if it's public. I think, and what we've seen is opportunities for not just liquidity, but steps along the way. So we've seen companies that get acquired just at IND or a proof of concept, or just the team, which you see in a lot of other industries. So I don't think it's as binary as it's gonna take 10 years before approval to see. And in fact, one of our portfolio companies had one of the first psychedelic exits had a ridiculous return because of the team and just where they were at with the proof of concept. So yes, to some extent, but also I think there's gonna be a lot of opportunities for investors along the way to make money. And of course everyone's, you could fill in the blank on whatever you think the blockbuster drug could be. But if you look at all these indications which have been around since the beginning of time, and in fact, one would argue they're increasing unfold with everything and how our world works in COVID financial systems. There'll be a lot of opportunities and inflection points along the way. Well, thank you for taking the time to speak with us today. I know that you're busy and I know that you've, like you said, you've been around this industry for a while. You're a wealth of information. So thank you for sharing your knowledge with us today and we will stay in touch. Awesome. Thank you so much, Deborah. Have a great rest of your week.